Merck & Co., Inc. is a global health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products. The company’s operations are managed on a products basis and include four operating segments: pharmaceutical, animal health, healthcare services, and alliances segments. Merck's performance demonstrates execution of its innovation strategy, with revenue growth in oncology, vaccines, hospital acute care, and animal health, focused investment in the research and development pipeline, and disciplined allocation of resources. The company has continued executing its strategy by entering into strategic collaborations and acquisitions, such as the collaboration with Eisai for the co-development and co-commercialization of lenvima, and the acquisition of Viralytics, which focuses on oncolytic immunotherapy treatments. Additionally, Merck announced an agreement to acquire Antelliq, a leader in digital animal identification, traceability, and monitoring solutions, highlighting the importance of digital technologies in enhancing operational capabilities. The company’s research and development expenses reflect higher clinical development spending and investment in discovery and early drug development, emphasizing the role of IT capabilities in supporting business needs and enhancing firm performance. Merck's leadership in oncology has been advanced through focused commercial execution and the achievement of important regulatory milestones, demonstrating the integration of technology capabilities in its operational processes. The company’s investment choices and strategic resource allocation are designed to enhance its competitive advantage and market responsiveness. Merck's financial activities include significant capital expenditures aimed at increasing future manufacturing capacity, which is essential for operational flexibility and business transformation. The company has also experienced challenges related to cyber-attacks that disrupted its operations, underscoring the need for robust IT governance and security measures. Merck's ability to mobilize and deploy IT-based resources in combination with other capabilities is critical in transforming the firm into a competitive force. The company’s strategic management practices involve continuous evaluation of its technology portfolio and the alignment of its business strategy with market dynamics. The integration of IT systems and processes is vital for optimizing operational efficiency and enhancing organizational effectiveness. Merck’s commitment to innovation partnerships and the development of its digital infrastructure further supports its objectives in the evolving healthcare landscape. The company's focus on actionable investments and the management of its technology resources are essential for maintaining market agility and responding effectively to consumer demands. Overall, Merck's approach to leveraging IT capabilities reflects its strategic alignment with organizational goals and its commitment to driving performance excellence in the healthcare sector.